Durability of the First Antiretroviral Treatment Regimen and Reasons for Change in Patients With HIV Infection

Torre, Javier de la; Aguilar, Ana; Santos, Jesús; Jiménez-Oñate, Francisco; Marcos, María Luisa Fernández; Núñez, Victoria; Olalla, Julián; Arco, Alfonso del; Prada, José Luis

doi:10.1310/hct1501-27

Cited by 12 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study conducted in the USA reported averages of 1.7 years in the first-line regimen, 1.2 years in the second-line regimen and 1.5 years in the third-line regimen 20. More recently, a Spanish population showed better tolerance to ARV treatments in regimens containing non-nucleoside reverse transcriptase inhibitors, with an average of 31 months reported 21. The reasons for shorter times between changes in the ARV regimen in these countries could be related to the fact that these locations have more alternatives for ARV treatment and better recording of ARs that allow the doctor to modify or change the ARV regimen.…”

Section: Discussionmentioning

confidence: 99%

Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico

Martínez-Salazar

Oaxaca-Navarro²,

Leija

et al. 2017

Eur J Hosp Pharm

View full text Add to dashboard Cite

ObjectiveTo analyse the most frequent self-reported adverse reactions (ARs), the durability and the causes of antiretrovirals (ARVs) regimens change, concomitant treatments and drug interactions related to the use of ARVs in a group of people living with HIV in Cuernavaca, Morelos, Mexico.Materials and methodsCross-sectional study conducted in a clinic specialising in HIV ‘CAPASITS-Cuernavaca’ in Mexico from February to June 2015. People who wanted to participate were given a questionnaire on demographic characteristics, adherence, concomitant treatments and ARs. To understand the clinical variables, the clinical records were reviewed. Quantitative variables were compared using Student’s t-test for normal data and the Mann-Whitney U test for non-normal data. For comparisons between categorical variables, the χ2 test was used. All tests used a significance level of 0.05.ResultsA total of 96 people participated, and 218 ARs (mean= 2.3±1.9) were found. The most frequently encountered ARs were dizziness (53.1%), insomnia (21.9%) and lucid dreams (17.7%). Twenty-three people (24%) were polymedicated, and 18 potential interactions were detected in 12 people.ConclusionsThe results suggest that a thorough analysis of the possible drug interactions should be performed for polymedicated people on ARV treatment and that a protocol should be designed for the monitoring and management of AR to ensure a good adherence to ARV treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico

Martínez-Salazar

Oaxaca-Navarro²,

Leija

et al. 2017

Eur J Hosp Pharm

View full text Add to dashboard Cite

show abstract

“…La sintomatología en ocasiones es inespecífica y si no se tiene un alto índice de sospecha puede no diagnosticarse o confundirse con otros procesos [1]. Por otro lado, las alteraciones gastrointestinales, en ocasiones atribuidas al tratamiento antirretroviral (TAR), son frecuentes en los pacientes con infección por el virus de la inmunodeficiencia humana (VIH) [2,3]. Por su ubicuidad y la poca especificidad de la sintomatología, es posible que una causa infradiagnosticada de las mismas sea la infección por el mencionado H. pylori [4].…”

Section: Introductionunclassified

Helicobacter pylori infection in the HIV + population: a comorbidity to think about

Valencia

Montejano²,

Moreno³

et al. 2020

Rev Esp Quimioter

View full text Add to dashboard Cite

show abstract

“…In a multicenter study of 600 patients who initiated ART between January 2007 and June 2010, toxicity of the therapeutic regimen (including disorders of kidney, liver, metabolism, gastrointestinal system, central nervous system, and skin) was the main reason for treatment discontinuation in 49% of patients. 81,82 Chronic or long -term toxicity resulting from the cumulative effect of sustained exposure can be particularly difficult to manage as it can be masked by or mingled with other comorbidities. In addition, long -term toxicity can manifest itself months or years after initial exposure.…”

Section: Introductionmentioning

confidence: 99%

Current challenges in the treatment of HIV

Seyler¹,

Lacor²,

Allard³

2018

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

At the 2014 International AIDS Conference in Melbourne, the Joint United Nations Program on HIV/AIDS (UNAIDS) proposed the 90-90-90 and 95-95-95 targets to accelerate efforts towards ending the AIDS epidemic as a public health threat by 2030. 4,5 The aim of this test-and-treat model is that by 2020 and 2030, respectively, at least 90% and 95% of all people living with HIV should be diagnosed, at least 90% and 95% of those diagnosed should be on cART, and at least 90% and 95% of those on cART should be virologically suppressed. Although the progress made so far is encouraging, HIV epidemic is far from over. According to a systematic analysis of national HIV treatment cascades from 69 countries, none of the countries had met the 90-90-90 targets. 6 Diagnosis (first target, 90% of all people with HIV diagnosed) ranged from 87% in the Netherlands to 11% in Yemen; treatment coverage (second target, 81% of all diagnosed people started on cART) ranged from 71% in Switzerland to 3% in Afghanistan; and viral suppression (third target, 73% of all people on cART virally suppressed) was between 68% in Switzerland and 7% in China. Moreover, the success in saving lives has not been matched with equal success in reducing new

show abstract

Durability of the First Antiretroviral Treatment Regimen and Reasons for Change in Patients With HIV Infection

Cited by 12 publications

References 26 publications

Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico

Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico

Helicobacter pylori infection in the HIV + population: a comorbidity to think about

Current challenges in the treatment of HIV

Contact Info

Product

Resources

About